Loading
Subsets of lung, bladder and breast cancers carry raised APOBEC enzyme activity that keeps generating new mutations, feeding resistance. Blocking APOBEC3 alongside a targeted drug aims not to kill cells but to slow the rate at which resistant variants arise; the inhibitors are still in discovery.
APOBEC3A and APOBEC3B mutagenesis is elevated in subsets of lung, bladder and breast cancers and has been mechanistically linked to acquired resistance to EGFR inhibitors in preclinical models. Small-molecule APOBEC3 inhibitors are in discovery. The proposal is an anti-evolution adjunct: combine an APOBEC inhibitor with the targeted agent from the first dose, with the aim not of killing cells but of reducing the rate at which resistant variants are generated.
One of the most cited trial reports Europe PMC returns for Osimertinib in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Anyone diagnosed with advanced lung cancer should have EGFR testing before treatment, because osimertinib as the first drug gives the longest disease control, protects the brain, and is well tolerated. Chemotherapy is not the first step for these patients. The remaining questions are whether to intensify upfront (adding chemotherapy or amivantamab) and how to treat resistance when it develops.
One of the most cited trial reports Europe PMC returns for Osimertinib in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares Tumour heterogeneity and clonal evolution, Osimertinib, Acquired resistance to every therapy, Non-small-cell lung cancer.
Shares FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Tumour heterogeneity and clonal evolution, Osimertinib, Acquired resistance to every therapy.
Shares FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib, Acquired resistance to every therapy, Non-small-cell lung cancer.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib, Acquired resistance to every therapy.
Shares Tumour heterogeneity and clonal evolution, Osimertinib, Acquired resistance to every therapy, Non-small-cell lung cancer.